At a glance
ClinicalIndex Comparison Record- ✓Metastatic renal cell cancer (any histologic subtype) with measurable/evaluable disease
- ✓Completed at least one prior line of systemic therapy (any number of prior therapies allowed, including prior nivolumab)
- ✓ECOG performance status 0-2
- ✓Absolute neutrophil count >750 cells/mm³
- ✕Cytotoxic chemotherapy ≤21 days prior to study treatment
- ✕Monoclonal antibody ≤4 weeks prior to study treatment
- ✕Other RCC-directed systemic therapy ≤2 weeks prior to study treatment
- ✕Known bleeding disorders (e.g., von Willebrand disease, hemophilia)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Ib/II Trial of Ibrutinib Plus Nivolumab in Patients With Previously-Treated Metastatic Renal Cell Cancer
In Brief
A Phase 2 clinical trial evaluating Ibrutinib and Nivolumab for Metastatic Renal Cell Cancer and Stage IV Renal Cell Cancer. Completed, enrolled 31 participants across 1 site.
Detailed Summary
This phase Ib/II trial studies how well ibrutinib and nivolumab work in treating patients with previously-treated kidney cancer that has spread to other parts of the body. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving Ibrutinib and nivolumab may work better in treating patients with metastatic kidney cancer.
Study Details
Timeline
Interventions
Given PO
Given IV